Pancreatic Cancer News and Research

RSS
Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.
University of Leicester study investigates early detection of pancreatic cancer

University of Leicester study investigates early detection of pancreatic cancer

Review summarises current data on markers for pancreatic cancer

Review summarises current data on markers for pancreatic cancer

New chemical compound offers a promising step for creating potential anti-cancer agents

New chemical compound offers a promising step for creating potential anti-cancer agents

Omeros' GPCR platform unlocks new drug targets against multiple sclerosis

Omeros' GPCR platform unlocks new drug targets against multiple sclerosis

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

Phase I results show Rogosertib is well tolerated in patients with advanced solid tumors

Phase I results show Rogosertib is well tolerated in patients with advanced solid tumors

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

American Cancer Society announces new research, training grants for fiscal year 2013

American Cancer Society announces new research, training grants for fiscal year 2013

Preclinical data for potent IDO pathway inhibitor presented at AACR 2013 annual meeting

Preclinical data for potent IDO pathway inhibitor presented at AACR 2013 annual meeting

Pancreatic Cancer Action Network researchers to participate in Rally for Medical Research

Pancreatic Cancer Action Network researchers to participate in Rally for Medical Research

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Berg to present new findings on cancer treatment, Interrogative Biology Platform at AACR meeting

Berg to present new findings on cancer treatment, Interrogative Biology Platform at AACR meeting

Anirban Maitra to lead pancreatic cancer research at UT MD Anderson Cancer Center

Anirban Maitra to lead pancreatic cancer research at UT MD Anderson Cancer Center

Men with Lynch syndrome face increased lifetime risk of prostate cancer

Men with Lynch syndrome face increased lifetime risk of prostate cancer

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

IGDRASOL to present updates on Cynviloq at AACR annual meeting

IGDRASOL to present updates on Cynviloq at AACR annual meeting

Researchers validate metabolomic analysis as new diagnostic method for pancreatic cancer

Researchers validate metabolomic analysis as new diagnostic method for pancreatic cancer

Virginia G. Piper Cancer Center Clinical Trials successfully tests cabozantinib

Virginia G. Piper Cancer Center Clinical Trials successfully tests cabozantinib

New study associates commonly used diabetes drugs with pancreatic cancer risk

New study associates commonly used diabetes drugs with pancreatic cancer risk

Pancreatic cancer cells' growth are fueled by metabolic pathway, scientists find

Pancreatic cancer cells' growth are fueled by metabolic pathway, scientists find

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.